 Curis Inc NASDAQ: CRIS has announced updated data from its ongoing Phase 12 study of CA-4948 in patients with acute myeloid leukemia AML or high-risk myelodysplastic syndromes MDS. Key findings were presented at the European Hematology Association 2021 Virtual Congress and included data from 22 patients 11 with high-risk MDS, 11 with AML. 